Abstract
Background: The non-vitamin K antagonist oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban are being administered in fixed doses without routine monitoring of anticoagulant activities. Despite this key advantage over vitamin K antagonists (VKAs), assessment of anticoagulant intensities is required in various clinical circumstances. We developed a multi-analyte approach for mass spectrometric analysis of NOACs in human plasma.
Methods: Plasma samples were precipitated with acetonitrile. Separation was achieved by liquid chromatography using a C18 column and a gradient elution within a run time of 2.5 min. Positive electrospray ionization was used and ion transitions monitored by a triple quadrupole mass spectrometer. Stable-isotope-labeled analogues of analytes were employed as internal standards for quantitative analysis. Certified external quality control samples were obtained for external validation.
Results: For all analytes, linearity could be demonstrated over the concentration range of 1–500 μg/L (R2>0.999), and the calculated limits of quantification were <1 μg/L. Results for inter- and intra-day assay precision and trueness were obtained using internal quality control samples and remained within the acceptance criterion of ±15%. External quality control samples were measured at the specified nominal values with inter- and intra-day precisions <14%. Matrix effects were fully compensated by co-eluting internal standards, which in turn did not relevantly influence ionization efficiency.
Conclusions: The method enables rapid and reliable simultaneous determination of NOAC concentrations in human plasma. It was successfully introduced into clinical practice; a case with rivaroxaban overdose is presented to exemplify the method’s applicability.
References
1. Ghanny S, Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol 2013;20:430–6.10.1097/MOH.0b013e328363c170Search in Google Scholar PubMed
2. Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 2014;74:1209–31.10.1007/s40265-014-0261-1Search in Google Scholar PubMed PubMed Central
3. Saraf K, Morris P, Garg P, Sheridan P, Storey R. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgrad Med J 2014;90:520–8.10.1136/postgradmedj-2014-132605Search in Google Scholar PubMed
4. Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 2014;14:175–89.10.1007/s40256-013-0061-0Search in Google Scholar PubMed
5. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014;124:1020–8.10.1182/blood-2014-03-563056Search in Google Scholar PubMed PubMed Central
6. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128–39.10.1016/j.jacc.2014.05.065Search in Google Scholar PubMed PubMed Central
7. Levy S. Newer clinically available antithrombotics and their antidotes. J Interv Card Electrophysiol 2014;40:269–75.10.1007/s10840-014-9910-2Search in Google Scholar PubMed
8. Baglin T, Keeling D, Kitchen S, British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159:427–9.10.1111/bjh.12052Search in Google Scholar PubMed
9. Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110:543–9.10.1160/TH13-03-0202Search in Google Scholar PubMed
10. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013;110:723–31.10.1160/TH13-04-0274Search in Google Scholar PubMed
11. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013;110:283–94.10.1160/TH12-12-0898Search in Google Scholar PubMed
12. Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 2014;36:597–605.10.1097/FTD.0000000000000059Search in Google Scholar PubMed
13. Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C, et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2014;100C:230–5.10.1016/j.jpba.2014.08.011Search in Google Scholar PubMed
14. Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014;12:1636–46.10.1111/jth.12702Search in Google Scholar PubMed
15. Schmitz EM, van den Heuvel DJ, Boonen K, van Dongen JL, Brunsveld L, van de Kerkhof D. Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring. Ned Tijdschr Klin Chem Labgeneesk 2013;38:142–4.Search in Google Scholar
16. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019–30.10.1021/ac020361sSearch in Google Scholar PubMed
17. Remane D, Meyer MR, Wissenbach DK, Maurer HH. Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultra-high-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization. Rapid Commun Mass Spectrom 2010;24:3103–8.10.1002/rcm.4736Search in Google Scholar PubMed
18. Remane D, Wissenbach DK, Meyer MR, Maurer HH. Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric procedures. Rapid Commun Mass Spectrom 2010;24:859–67.10.1002/rcm.4459Search in Google Scholar PubMed
19. ICH. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Harmonised Tripartite Guideline, Validation of analytical procedures: Text and Methodology Q2(R1). Available at http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html. 2005. Accessed on 3 July, 2014.Search in Google Scholar
20. Food and Drug Administration. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry, Bioanalytical Method Validation. Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm. 2001. Accessed on 26 June, 2014.Search in Google Scholar
21. Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 2013;78–79:150–3.10.1016/j.jpba.2013.02.007Search in Google Scholar PubMed
22. Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran – a direct thrombin inhibitor – in human plasma. J Pharm Biomed Anal 2012;58:152–6.10.1016/j.jpba.2011.09.018Search in Google Scholar PubMed
23. Rohde G. Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;872:43–50.10.1016/j.jchromb.2008.07.015Search in Google Scholar PubMed
24. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155–63.10.1016/0010-4825(92)90011-BSearch in Google Scholar
25. Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 2013;69:1617–33.10.1007/s00228-013-1510-zSearch in Google Scholar PubMed
26. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants – reasons, methods and current limitations. J Thromb Thrombolysis 2013;36:187–94.10.1007/s11239-013-0907-ySearch in Google Scholar PubMed
27. Eliasson E, Lindh JD, Malmstrom RE, Beck O, Dahl ML. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 2013;69(Suppl 1):25–32.10.1007/s00228-013-1504-xSearch in Google Scholar PubMed
Supplemental Material
The online version of this article (DOI: 10.1515/cclm-2014-1108) offers supplementary material, available to authorized users.
©2015 by De Gruyter
